Estonia’s Health Insurance Fund is evaluating whether to broaden coverage of a medication currently approved for Type 2 diabetes to include individuals struggling with obesity. The potential expansion hinges on the results of a cost-benefit analysis expected in the autumn. Currently, the drug is not routinely prescribed for weight management alone. If approved, the change would offer a new pharmaceutical option for obesity treatment within the Estonian healthcare system. The EHIF aims to determine if the drug’s benefits for obese patients justify the financial investment. This consideration reflects a growing recognition of obesity as a chronic health condition requiring medical intervention. The analysis will inform a decision on whether to include the medication on the list of reimbursable drugs.